The Medical Advisor

Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 2026 Quick Answer Semaglutide (“sema”), tirzepatide (“tirz”), and retatrutide (“reta”) represent three stages in the evolution of incretin-based weight-loss medications: a single GLP-1 receptor agonist, a dual GIP/GLP-1 receptor agonist, and an investigational triple GIP/GLP-1/glucagon receptor agonist, respectively. Semaglutide is an FDA-approved GLP-1 receptor agonist that has demonstrated average weight loss of approximately 15% in clinical trials, with some individuals losing more. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated average weight loss of up to approximately 21–22% in trials. Retatrutide, an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, has shown promising weight-loss results in clinical trials but is not yet FDA-approved. What changed in this update (Oct 2026): replaced pre-Phase-3 esti...

Updated August 2026 · Evidence-Ranked Edition This article has been reorganised to rank all 33 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy. ⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024 Introduction Most mainstream guides to "alternative cancer treatments" — including the widely cited Mayo Clinic...